Showing results (1-10 of 447) with videos related to

Sort By:
Pageof 45
Japanese Journal of Clinical Oncology|December 20, 2023
Thoracic SMARCA4-deficient undifferentiated tumor: current knowledge and future perspectivesYuki Shinno, Yuichiro Ohe,
JTO Clinical and Research Reports|September 30, 2021
The Long Half-Life of Programmed Cell Death Protein 1 Inhibitors May Increase the Frequency of Immune-Related Adverse Events After Subsequent EGFR Tyrosine Kinase Inhibitor TherapyYuki Shinno, Yasushi Goto, Mayu Ohuchi, et al.
Cancer Immunology, Immunotherapy : CII|August 14, 2021
Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expressionHiroshi Takumida, Hidehito Horinouchi, Ken Masuda, et al.
JTO Clinical and Research Reports|February 5, 2025
EGFR-Mutated Lung Adenocarcinoma With Li-Fraumeni Syndrome: The Imperative for Germline Testing in Patients With a Family History, a Case ReportHiroyuki Fujii, Yusuke Okuma, Makoto Hirata, et al.
JTO Clinical and Research Reports|May 2, 2022
Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With AlectinibYuki Takeyasu, Tatsuya Yoshida, Ken Masuda, et al.
Respiratory Investigation|July 4, 2024
The remarkable antitumor efficacy of corticosteroid treatment in patients with refractory thymomasTomohiro Tanaka, Yasushi Goto, Ken Masuda, et al.
Respiratory Investigation|January 1, 2022
Correlation between body mass index and efficacy of anti-PD-1 inhibitor in patients with non-small cell lung cancerAkiko Tateishi, Hidehito Horinouchi, Tatsuya Yoshida, et al.
Lung Cancer (Amsterdam, Netherlands)|February 28, 2025
Evolving treatments and prognosis in Stage IV non-small cell lung cancer: 20 years of progress of novel therapiesHironori Satoh, Yusuke Okuma, Yuki Shinno, et al.
JTO Clinical and Research Reports|February 16, 2024
Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR MutationsYuki Takeyasu, Tatsuya Yoshida, Ken Masuda, et al.
Anticancer Research|January 30, 2026
Clinical Activity of MET-TKIs in METex14 Skipping NSCLC With Poor Performance StatusYoh Yamaguchi, Tatsuya Yoshida, Ryoko Inaba Higashiyama, et al.
Pageof 45